Mouse methylome studies SRP413488 Track Settings
 
Methylation state of latent and proliferative metastatic tumor cells [Breast Cancer]

Track collection: Mouse methylome studies

+  All tracks in this collection (560)

Maximum display mode:       Reset to defaults   
Select views (Help):
CpG reads ▾       PMD       CpG methylation ▾       AMR      
Select subtracks by views and experiment:
 All views CpG reads  PMD  CpG methylation  AMR 
experiment
SRX18752180 
SRX18752181 
SRX18752182 
SRX18752183 
SRX18752184 
SRX18752185 
SRX18752186 
SRX18752187 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 Configure
 SRX18752180  CpG methylation  Breast Cancer / SRX18752180 (CpG methylation)   Data format 
hide
 Configure
 SRX18752181  CpG methylation  Breast Cancer / SRX18752181 (CpG methylation)   Data format 
hide
 Configure
 SRX18752182  CpG methylation  Breast Cancer / SRX18752182 (CpG methylation)   Data format 
hide
 Configure
 SRX18752183  CpG methylation  Breast Cancer / SRX18752183 (CpG methylation)   Data format 
hide
 Configure
 SRX18752184  CpG methylation  Breast Cancer / SRX18752184 (CpG methylation)   Data format 
hide
 Configure
 SRX18752185  CpG methylation  Breast Cancer / SRX18752185 (CpG methylation)   Data format 
hide
 Configure
 SRX18752186  CpG methylation  Breast Cancer / SRX18752186 (CpG methylation)   Data format 
hide
 Configure
 SRX18752187  CpG methylation  Breast Cancer / SRX18752187 (CpG methylation)   Data format 
    
Assembly: Mouse Jun. 2020 (GRCm39/mm39)

Study title: Methylation state of latent and proliferative metastatic tumor cells
SRA: SRP413488
GEO: not found
Pubmed: not found

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Title
SRX18752180 Breast Cancer 0.596 15.7 46761 10613.7 1725 1066.7 2213 518405.8 0.989 GSM6855724: latent metastatic 4T1 - replicate 1; Mus musculus; Bisulfite-Seq
SRX18752181 Breast Cancer 0.611 13.1 40302 10432.8 3543 1211.3 1587 730837.1 0.988 GSM6855725: latent metastatic 4T1 - replicate 2; Mus musculus; Bisulfite-Seq
SRX18752182 Breast Cancer 0.626 2.1 24202 11162.0 34 1377.4 849 1307370.4 0.984 GSM6855726: latent metastatic 4T1 - replicate 3; Mus musculus; Bisulfite-Seq
SRX18752183 Breast Cancer 0.596 11.1 41158 11800.7 609 984.6 1695 683385.7 0.988 GSM6855727: latent metastatic 4T1 - replicate 4; Mus musculus; Bisulfite-Seq
SRX18752184 Breast Cancer 0.592 13.8 45772 10965.0 731 1003.0 1771 655952.6 0.988 GSM6855728: proliferative metastatic 4T1 - replicate 1; Mus musculus; Bisulfite-Seq
SRX18752185 Breast Cancer 0.594 11.3 41584 11601.5 567 1024.2 1759 661467.0 0.988 GSM6855729: proliferative metastatic 4T1 - replicate 2; Mus musculus; Bisulfite-Seq
SRX18752186 Breast Cancer 0.598 8.8 36995 12308.4 473 1036.1 1505 781625.4 0.987 GSM6855730: proliferative metastatic 4T1 - replicate 3; Mus musculus; Bisulfite-Seq
SRX18752187 Breast Cancer 0.599 7.0 33421 13378.6 231 1089.3 1375 836911.1 0.987 GSM6855731: proliferative metastatic 4T1 - replicate 4; Mus musculus; Bisulfite-Seq

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.